IL-13 signaling has also been reported to induce lipogenesis and bile-dependent steatosis (63).The production of IL-4, IL-5 and IL-13 can be promoted by IL-33 (64), treatment with which can promote liver fibrosis but also restrict lipid storage in hepatocytes and result in slightly decreased liver injury in a NASH mouse model (65). Here, IL13 is linked to metabolic dysfunction-associated steatohepatitis.